Introduction

• Background
• Overview of the legal basis

General methods of IQWiG

• Patient-relevant medical benefit or harm
• Specific methodological aspects of benefit assessments
• Information procurement and assessment
• Case studies

Dossier preparation and assessment

• Dossier structure
• Case studies

Benefit assessment by the Federal Joint Committee

• Consultation in the context of the (early) benefit assessment
• Decisions of the G-BA
• Data collection accompanying the application
• EU-HTA
• Case studies

Pricing according to AMNOG

• Framework agreement
• Rebate negotiations, reimbursement amount
• Arbitration board

Drug expenditure control according to the AMNOG

• Rebate agreements, target agreements, pay-for-performance agreements, etc.

Further development of the organisation of cost-effectiveness and pricing of medicinal products

• Targets and willingness to pay

Reimbursement of medicinal products

• Organisation and basic principles of SHI
• SHI control instruments for the supply of medicines
• Case studies

Cost-benefit assessment

• Legal framework
• Cost-benefit assessment process
• Methodological requirements for the cost-benefit assessment

EU-HTA

• Legal basis
• Status of the discussions
• Interaction with AMNOG process
• DiGA